Imunon highlights 14.7-month overall survival gain in Phase 2 IMNN-001 ovarian cancer study as Phase 3 trial advances
IMNN•Imunon highlighted final Phase 2 results showing a 14.7-month overall survival gain for IMNN-001 in newly diagnosed advanced ovarian cancer. Enrollment in the Phase 3 OVATION 3 trial is ahead of plan, with completion targeted for the first quarter of 2029.
1. Phase 2 results
Imunon highlighted final Phase 2 results for IMNN-001, describing them as supportive evidence for its ongoing Phase 3 OVATION 3 trial, where survival is the primary endpoint. Management said the treatment avoids the systemic safety issues that derailed earlier IL-12 programs.
2. Phase 3 enrollment
Enrollment in OVATION 3 is running ahead of plan, and Imunon said its target of completing enrollment in the first quarter of 2029 remains intact. The company also cited early observations from an MRD study that suggest improved disease-clearance signals, while noting the dataset is too small for efficacy conclusions.
